Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

Contributed by: PR Newswire

Tags

PHOTOCURE-Asieris

More Like This

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress

Photocure ASA: Results for the fourth quarter of 2023